Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 4/20 | 0.42 |
| ▸ | PGK2 | P07205 | 4/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5987314 | 0.79 | PGK1 (0.47) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL4009976 | 0.78 | PGK1 (0.46) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL2033188 | 0.71 | PGK1 (0.38) | PGK1PGK2PTPN5PTPN1ALDH1A1 | |
| SCHEMBL5404370 | 0.70 | PGK1 (0.42) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL4005577 | 0.68 | PGK1 (0.44) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL5391918 | 0.67 | PGK1 (0.42) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL3737962 | 0.66 | TSHR (0.51) | PGK1PGK2PTPN5PTPN1ALDH1A1 | |
| SCHEMBL11694096 | 0.65 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11691152 | 0.65 | GRIN2D (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28672161 | 0.63 | TSHR (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | PGK1 1901/4885PGK2 1459/4885GRIN2D 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.